Tumor necrosis factor-α is a novel biomarker for peripheral neuropathy in type II diabetes mellitus: a clinical and electrophysiological study

Mohja A. El-Badawy, Dina A.B. Farrag, Samia M.R. Abd El-Rehem, Amira R. El-Mahdi, Alyaa A. El-Sherbeny, Emad A.M. Abdel Hady, Hoda A. Abdel-Sattar, Doaa M. Abdelaziz

Departments of Physical Medicine, Rheumatology and Rehabilitation, Internal Medicine, Allergy and Immunology, Internal Medicine, Endocrinology, Clinical Pathology, Faculty of Medicine, Ain Shams University Hospital, Ain Shams University, Cairo, Egypt

Correspondence to Mohja A. El-Badawy, MD, Assistant Professor of Physical Medicine, Rheumatology & Rehabilitation, Faculty of Medicine, Ain Shams University, 211 Abdel-Hamid Keshk Street, Hadaeq El-Quba, 11646 Cairo, Egypt; Tel: +20 100 504 8716/20 111 143 4418; e-mail: mohjaaelbadawy@gmail.com

Received 3 November 2016
Accepted 11 January 2017

Egyptian Rheumatology & Rehabilitation 2017, 44:83–90

Original article 83

Background
Tumor necrosis factor-α (TNF-α) is an adipocytokine locally produced by Schwann cells and has a role in nerve regeneration and regulation of apoptosis. The role of TNF-α in the development of diabetic peripheral neuropathy (DPN) is controversial.

Objective
The objective of this study was to evaluate TNF-α serum level in a group of type II diabetes mellitus (DM) patients with and without neuropathy in comparison with healthy age-matched control group.

Design
This is a cross-sectional case–control study.

Settings
The study was conducted in outpatient clinics of the diabetes and physical medicine, rheumatology, and rehabilitation departments.

Patients
Ninety patients diagnosed with type II diabetes were included in the study.

Main outcome measures
All patients were assessed for clinical neuropathy using neuropathy symptom score and neuropathy disability score. All patients underwent nerve conduction studies of both upper and lower limbs. They were divided into two groups: group I with confirmed DPN (n=60) and group II with DM but no peripheral neuropathy (n=30). Serum TNF-α level was measured in all previous DM patients (90 patients) in addition to 48 healthy age-matched controls.

Results
A statistically significant difference was detected between serum TNF-α level in controls and diabetic patients. Similarly, a significant difference was detected between its level in non-DPN patients and confirmed DPN patients, being higher in the latter. A positive significant correlation has been detected between TNF-α level and patients’ age, as well as blood cholesterol level. A positive significant correlation has been found between TNF-α level and both neuropathy symptom score and neuropathy disability score. A significant negative correlation had been detected between TNF-α level and motor amplitudes of both tibial nerves.

Conclusion
Serum TNF-α level might be a potential biomarker for peripheral neuropathy in type II DM.

Keywords:
peripheral neuropathy, tumor necrosis factor-α, type II diabetes mellitus

Introduction
Diabetic peripheral neuropathy (DPN) is a common complication of diabetes mellitus (DM) that can have a serious impact on the quality of life [1].

A number of neuropoietic cytokines that are produced locally by residual and infiltrating macrophages, lymphocytes, mast cells, Schwann cells, and sensory neurons exhibit pleiotropic effects on glia cells and neurons, which is vital for the homeostasis of the peripheral, central, and autonomic nervous system. These neuropoietic cytokines include interleukin-1, interleukin-6, transforming growth factor β-1, leukemia inhibitory factors, ciliary neurotrophic factors, and tumor necrosis factor-α (TNF-α) [2].

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work noncommercially, as long as the author is credited and the new creations are licensed under the identical terms.
TNF-α is locally produced by Schwann cells and has a role in peripheral nerve regeneration and regulation of apoptosis [2]. The metabolic changes induced by hyperglycemia lead to disturbance of cytokine control [3].

Under chronic hyperglycemia, endogenous TNF-α production is accelerated in microvascular and neural tissues, leading to increased microvascular permeability, hypercoagulability, and nerve damage, thus promoting the development of characteristic lesions of diabetic microangiopathy and polyneuropathy [4].

The effect of TNF-α on neurons seems to be mediated, directly and/or indirectly, by the phosphorylation of extracellular-regulated kinase and P38 mitogen-activated protein kinase [5], translocation of nuclear factor κB to the nucleus, and activation of Cox-2-dependent prostanoid release [6].

TNF-α also activates nuclear factor κB for the initiation of nitric oxide synthase, and nitric oxide production. Inhibition of serum TNF-α and nitric oxide levels with insulin attenuates DN pain, as TNF-α plays an important role in the development of DPN [7].

TNF-α increases the permeability of the endothelium through the release of nitric oxide [8] and increases thrombogenesis through plasminogen activator inhibitor-1 overexpression [9].

The present study is designed to explore the serum level of TNF-α in type II diabetic patients as a risk factor for the development of DPN.

**Patients and methods**

The present study is a cross-sectional conducted in the Ain Shams University Hospital. It includes ninety patients with type II DM according to the American Diabetes Association criteria [10] whose ages ranged from 35 to 60 years. Patients were recruited at random from the diabetes and physical medicine, rheumatology, and rehabilitation outpatient clinics. The study was approved by the local ethics committee and an informed consent was obtained from all participants. The 90 DM patients are subdivided into 60 patients with peripheral neuropathy (PN) (group I) and 30 patients with no PN (group II).

PN due to causes other than diabetes was also excluded, such as alcohol abuse, liver or renal disease, metabolic or nutritional disorders, rheumatologic or endocrine diseases, inflammatory diseases, or monoclonal gammopathies. Patients with trauma, limb swelling, or skin lesion that could interfere with nerve conduction were excluded.

**Patient data and anthropometric measurement**

Age, diabetes duration, weight, height, and blood pressure were recorded. BMI was calculated using the Quetelet formula (weight in kilograms divided by the square of height in meters).

Patients underwent full history taking and clinical examination. Patient symptoms due to PN was assessed by the neuropathy symptom score (NSS) [11]. Patients were asked about their experience of pain or discomfort in the legs: if the patient described burning, numbness, or tingling, a score of 2 was assigned; fatigue, cramping, or aching scored 1. The presence of symptoms in the feet was assigned a score of 2, the calves 1, and elsewhere a score of 0. Nocturnal exacerbation of symptoms scored 2 versus 1 for both day and night and 0 for daytime alone. A score of 1 was added if the symptoms had ever awakened the patient from sleep. The patients were asked if any maneuver could reduce the symptoms: walking was assigned a score of 2, standing as 1, and sitting or lying down was 0. The maximum symptom score was 9 [12].

Neuropathy disability score (NDS) was used for grading DM-PN severity, which is a composite score (0–10). NDS assesses four items: the presence or absence of pain sensation (pin prick), vibration sensation with a tuning fork, the temperature sensation on the dorsum of the foot with cold and warm rods, and Achilles tendon reflexes (present, reinforcements, absent). On the basis of the outcome, Young et al. [12], have proposed a neuropathy severity classification system. According to this system, the classification is as follows: no PN (0–2), mild PN (3–5), moderate PN (6–8), and severe PN (9–10).

**Laboratory investigations**

Six milliliters of venous blood was collected under complete aseptic precautions from each subject. The collected blood was divided among an EDTA tube for glycated hemoglobin and a plain test tube for serum separation. After clotting, samples were centrifuged at 1000 g for 15 min and sera were separated. Hemolyzed samples were discarded, and repeated freezing and thawing was avoided.

Serum glucose, total serum cholesterol, and triglycerides were determined by enzymatic colorimetric assay (Synhron CX-9; Beckman Instruments Inc., Fullerton, California, USA). High-density lipoprotein cholesterol
was determined enzymatically in the supernatant after dextran–magnesium-induced precipitation of other lipoproteins. Low-density lipoprotein cholesterol was calculated using the Friedewald formula.

HbA1c levels were determined by an ion-exchange HPLC method (Bio-Rad D10 HbA1c; BioRad Laboratories, Hercules, California, USA).

Quantification of serum TNF-α in serum samples was performed using sandwich ELISA (Assay pro LLC, St Charles, Missouri, USA) according to the manufacturer’s protocol. The detection limit was 0.01 ng/ml (Assay pro LLC). Serum TNF-α was measured in all patients and 48 age-matched and sex-matched healthy controls.

Electrophysiological studies

Electrophysiological evaluation was performed in all DM patients to confirm PN using nerve conduction studies (by using Toennies Neuroscreen Plus; Toennies, Hoechberg, Germany). In motor studies, we used parameters of the sweep of 5 ms/division and a gain of 4 mV. In sensory studies, the sweep was adjusted at 2 ms and gain at 20 μV. The tests were performed at room temperature.

In the lower limbs, peroneal nerve and tibial nerve motor conduction studies and sural sensory nerve conduction study were performed bilaterally. In the upper limbs, both median and ulnar nerves motor nerve conduction and median sensory nerve conduction studies were performed.

Diagnosis of diabetic peripheral neuropathy

DPN was categorized into two levels, according to clinical findings and nerve conduction results based on the modified Toronto Expert Consensus [13]: non-DPN, in which DM patients had neither clinically evident PN nor abnormal nerve conduction tests, and confirmed DPN, in which DM patients had at least one abnormal nerve parameter of nerve conduction velocity (NCV), amplitude, and latency in two nerves among the median, peroneal, and sural nerves [14] with or without clinical signs and symptoms. An abnormality is more than or equal to 99th or less than or equal to first percentile according to Kimura [15].

The category of only clinically evident DPN could not be found in our patients. Clinically evident DPN was defined for patients who had at least two positive results among sensory symptoms, signs, or reflex abnormalities in accordance with a distal symmetrical polyneuropathy, and with the normal nerve conduction studies.

Statistical analysis

Continuous variables are expressed as mean and SD. Categorical variables are expressed as frequencies and percents. Student’s t-test and Mann–Whitney test were used to assess the statistical significance of the difference between quantitative variables. Spearman’s correlation was used to assess the correlation between TNF and other parameters. A significance level of \( P \) value less than 0.05 was used in all tests. All statistical procedures were carried out using SPSS, version 20 for Windows (SPSS Inc., Chicago, Illinois, USA).

Results

Our DM patients were divided into two groups based on the presence or absence of PN. Group I consists of 60 DM patients with PN and group II consists of 30 DM patients with no PN in addition to 48 healthy age-matched and sex-matched controls. The demographic and clinical characteristics of both groups of diabetic patients are shown in Table 1. No statistically significant differences were found between both groups at baseline for anthropometric parameters and medications. However, statistically significant differences were found between groups in disease duration and both scores of neuropathy disability symptoms and of clinical PN. Diabetic patients in both groups showed nonsignificant differences in fasting plasma glucose, postprandial glucose, HbA1c, and serum lipids (Table 2).

Motor nerve conduction velocities and amplitudes and distal latencies in group I diabetic patients with PN were compared with group II diabetic patients without PN in Table 3.

Motor nerve amplitudes of median, ulnar, peroneal, and tibial nerves were found to be significantly decreased \( (P<0.05) \) in group I, whereas motor nerve conduction velocities of the studied nerves, sensory conduction velocities, and sensory amplitudes of median and sural nerve differences were not statistically significant. Both tibial motor distal latencies were the only ones to show a statistically significant difference between both groups.

We found a mixed axonal and demyelinating neuropathy in 65% and a demyelinating neuropathy in 35% of DPN patients (group I).

We found a highly significant increase in serum TNF-α in our diabetic patients when compared with the control group \( (P=0.000) \) (Table 4).
Group I patients with PN showed a significant increase in serum TNF-α when compared with group II patients without PN \((P=0.038)\) (Table 5).

Serum TNF-α showed a significant positive correlation with age \((P=0.016)\), serum cholesterol level \((P=0.04)\), score of neuropathy disability symptoms \((P=0.018)\), and score of clinical PN \((P=0.039)\), whereas no significant correlations were found with BMI, duration of diabetes, and all studied biochemical tests in DPN patients (Table 6).

Serum TNF-α showed a nonsignificant negative correlation with conduction velocities of all studied motor and sensory nerves in DPN patients (Table 7).

Serum TNF-α showed a nonsignificant negative correlation with amplitudes of all studied motor and sensory nerves in DPN patients (Table 7).

**Table 1 Baseline characteristics of two groups of patients (group I: confirmed diabetic peripheral neuropathy, group II: no diabetic peripheral neuropathy)**

| Characteristic                          | Groups       | N  | Mean±SD     | P-value | Significance |
|----------------------------------------|--------------|----|-------------|---------|--------------|
| Age                                    | Group I      | 60 | 48.05±11.62 | 0.25    | NS           |
|                                        | Group II     | 30 | 42.40±13.55 |         |              |
| Sex (female) \([n (\%)]\)             | Group I      | 60 | 39 (65)     | 0.416   | NS           |
|                                        | Group II     | 30 | 24 (80)     |         |              |
| DM duration (years)                    | Group I      | 60 | 3.46±1.92   | 0.012   | S            |
|                                        | Group II     | 30 | 1.73±0.98   |         |              |
| Weight                                 | Group I      | 60 | 79.85±16.53 | 0.273   | NS           |
|                                        | Group II     | 30 | 87.40±19.26 |         |              |
| Height                                 | Group I      | 60 | 165.65±10.97| 0.763   | NS           |
|                                        | Group II     | 30 | 164.50±6.43 |         |              |
| BMI                                    | Group I      | 60 | 28.93±6.47  | 0.170   | NS           |
|                                        | Group II     | 30 | 32.50±6.75  |         |              |
| SBP                                    | Group I      | 60 | 131±18.89   | 0.235   | NS           |
|                                        | Group II     | 30 | 122.80±13.93|         |              |
| DBP                                    | Group I      | 60 | 83.75±13.27 | 0.409   | NS           |
|                                        | Group II     | 30 | 80.00±6.67  |         |              |
| Score of neuropathy disability symptoms| Group I      | 60 | 6.10±1.65   | 0.000   | HS           |
|                                        | Group II     | 30 | 1.10±0.88   |         |              |
| Neuropathy symptom score               | Group I      | 60 | 6.00±1.75   | 0.000   | HS           |
|                                        | Group II     | 30 | 1.20±1.14   |         |              |
| Medication                             |             |    |             |         |              |
| Insulin \([n (\%)]\)                  | Group I      | 60 | 27 (45)     | 0.803   | NS           |
|                                        | Group II     | 30 | 12 (40)     |         |              |
| Oral hypoglycemic \([n (\%)]\)        | Group I      | 60 | 33 (55)     | 0.803   | NS           |
|                                        | Group II     | 30 | 18 (60)     |         |              |

DBP, diastolic blood pressure; DPN, diabetic peripheral neuropathy; HS, highly significant; S, significant; SBP, systolic blood pressure.

**Table 2 Biochemical characteristics of type 2 diabetic patients with (group I) and without peripheral neuropathy (group II)**

| Characteristic                          | Neutrophy | N  | Mean±SD     | P-value | Significance |
|----------------------------------------|-----------|----|-------------|---------|--------------|
| Fasting plasma glucose (mg/dl)         | Group I   | 60 | 176.90±67.41| 0.592   | NS           |
|                                        | Group II  | 30 | 163.30±58.90|         |              |
| Postprandial glucose (mg/dl)           | Group I   | 60 | 272.90±96.80| 0.687   | NS           |
|                                        | Group II  | 30 | 258.40±81.19|         |              |
| HbA1c (%)                              | Group I   | 60 | 8.72±1.65   | 0.803   | NS           |
|                                        | Group II  | 30 | 8.86±1.05   |         |              |
| Serum cholesterol (mg/dl)              | Group I   | 60 | 212.40±45.89| 0.226   | NS           |
|                                        | Group II  | 30 | 235.00±49.64|         |              |
| Serum triglycerides (mg/dl)            | Group I   | 60 | 140.50±38.58| 0.335   | NS           |
|                                        | Group II  | 30 | 154.50±33.00|         |              |
| LDL cholesterol (mg/dl)                | Group I   | 60 | 117.20±28.95| 0.991   | NS           |
|                                        | Group II  | 30 | 117.32±21.81|         |              |
| HDL cholesterol (mg/dl)                | Group I   | 60 | 45.50±11.49 | 0.374   | NS           |
|                                        | Group II  | 30 | 49.90±14.58 |         |              |

HDL, high density lipoprotein; LDL, low density lipoprotein.
sensory nerves except for the motor amplitude of both tibial nerves where a significant negative correlation was found in DPN patients (Table 8).

Discussion

DPN is one of the most common chronic complications of DM and is the leading cause of disability among patients with type 2 DM.

Mechanisms underlying the development of DPN have not been fully elucidated. Previous studies have shown the multifactorial nature of DPN that it can be attributed to genetic factors, hyperglycemia, abnormal fat and protein metabolism, and vascular abnormalities [16–18].

Multiple immune factors were evidenced in the occurrence of DPN [19,20]. TNF-α is an important immune cytokine involved in the development of many inflammatory, infectious, and autoimmune diseases, and functions to inhibit tumor cells, increase phagocytic activity of neutrophils, and stimulate the production of other cytokines [21].

The immune response, in which self-antigen components get exposed, is the main factor leading to demyelination in case of DPN. T cells activated by these antigens produce different cytokines, including TNF-α, which induces a positive feedback loop cycle to further increase its own immune response that mediates the inflammatory reaction [21].

| Table 3 Comparison of electrophysiological studies between two groups of patients (groups I and II) |
|-------------------------------------------------|---------------------------------|---------------------------------|
| Groups                                          | N     | Right Mean±SD | P      | Significance | Left Mean±SD | P      | Significance |
|-------------------------------------------------|-------|----------------|--------|--------------|--------------|--------|--------------|
| Median motor CV                                | Group I | 60             | 51.26±7.35 | 0.299 | NS           | 52.04±9.33 | 0.981 | NS           |
|                                                 | Group II | 30             | 54.08±5.82 | 0.159 | NS           | 51.95±10.41 | 0.201 | NS           |
| Median motor DL                                | Group I | 60             | 4.24±2.01  | 0.003 | S            | 3.98±1.73  | 0.007 | S            |
|                                                 | Group II | 30             | 3.30±0.43  | 0.019 | NS           | 3.23±0.64  | 0.178 | NS           |
| Median motor amp.                              | Group I | 60             | 9.05±3.76  | 0.997 | NS           | 52.69±12.77| 0.178 | NS           |
|                                                 | Group II | 30             | 8.53±3.86  | 0.116 | NS           | 58.96±9.14| 0.286 | NS           |
| Ulnar motor CV                                 | Group I | 60             | 2.62±0.52  | 0.053 | S            | 2.56±0.63  | 0.024 | S            |
|                                                 | Group II | 30             | 3.30±0.37  | 14.65±1.70|              | 14.65±1.70|              |              |
| Ulnar motor DL                                 | Group I | 60             | 11.87±3.64 | 0.232 | NS           | 26.15±13.14| 0.146 | NS           |
|                                                 | Group II | 30             | 14.36±1.89 | 0.264 | NS           | 34.09±13.51| 0.256 | NS           |
| Ulnar motor amp.                               | Group I | 60             | 30.41±12.37| 0.113 | NS           | 4.17±2.19  | 0.256 | NS           |
|                                                 | Group II | 30             | 35.24±11.59| 0.113 | NS           | 3.27±1.46  | 0.256 | NS           |
| Peroneal motor CV                              | Group I | 60             | 43.21±8.78 | 0.565 | NS           | 40.84±8.83 | 0.137 | NS           |
|                                                 | Group II | 30             | 45.41±7.65 | 0.565 | NS           | 45.44±6.61| 0.273 | NS           |
| Peroneal motor DL                              | Group I | 60             | 4.42±1.84  | 0.007 | S            | 2.82±0.25  | 0.001 | S            |
|                                                 | Group II | 30             | 4.02±1.55  | 2.82±0.25 |              | 3.66±0.66  | 0.273 | NS           |
| Tibial motor CV                                | Group I | 60             | 30.90±11.73| 0.272 | NS           | 38.68±9.84 | 0.288 | NS           |
|                                                 | Group II | 30             | 40.32±5.66 | 0.272 | NS           | 42.51±7.38| 0.288 | NS           |
| Tibial motor DL                                | Group I | 60             | 5.21±1.53  | 0.005 | S            | 5.22±1.51  | 0.002 | S            |
|                                                 | Group II | 30             | 3.49±1.32  | 5.22±1.51 |              | 3.49±0.93  | 0.002 | S            |
| Tibial motor amp.                              | Group I | 60             | 7.35±6.61  | 0.002 | S            | 7.47±5.74  | 0.003 | S            |
|                                                 | Group II | 30             | 16.13±6.70 | 7.47±5.74 |              | 14.95±6.44| 0.003 | S            |
| Sural sensory CV                                | Group I | 60             | 35.60±15.01| 0.251 | NS           | 34.85±12.75| 0.201 | NS           |
|                                                 | Group II | 30             | 41.44±5.43 | 0.251 | NS           | 41.62±11.87| 0.201 | NS           |
| Sural sensory DL                                | Group I | 60             | 4.94±2.80  | 0.080 | NS           | 4.89±2.43  | 0.567 | NS           |
|                                                 | Group II | 30             | 3.30±0.48  | 4.89±2.43 |              | 6.22±8.61  | 0.567 | NS           |
| Sural sensory amp.                              | Group I | 60             | 26.09±14.50| 0.116 | NS           | 23.48±17.35| 0.307 | NS           |
|                                                 | Group II | 30             | 15.96±12.20| 23.48±17.35|              | 16.20±7.34| 0.307 | NS           |

Amp., amplitude; CV, conduction velocity; DL, distal latency; Lt, left; Rt, right; S, significant.
In the present study, we measured the serum level of TNF-α in type II DM patients with PN and compared such a level with its level in patients with type II DM without neuropathy.

Our study results support the hypothesis that a relationship between serum TNF-α levels and DPN exists. Serum TNF-α was found to be statistically significantly higher in diabetic patients as compared with age-matched and sex-matched controls. Furthermore, serum TNF-α level in DPN patients was found to be much higher than in non-DPN patients (i.e. only DM with no PN).

We found a mixed axonal and demyelinating neuropathy in 65% and a demyelinating neuropathy in 35% of DPN patients. The pattern of neuropathy noted in the present study is consistent with previous neurophysiologic studies undertaken in type 2 diabetic patients [22–25].

In the present study, levels of TNF-α in the DPN patient showed a nonsignificant negative correlation with motor NCV in the median, ulnar, common peroneal, and tibial nerves and sensory NCV in median and sural nerves. Serum TNF-α in DPN patients showed a significant negative correlation with motor amplitudes of both tibial nerves, and no significant correlations were found with motor and sensory amplitudes of other studied nerves.

However, levels of TNF-α in DPN patient showed statistically significant positive correlations with score of neuropathy disability symptoms (NDS) and score of clinical PN (NSS).

Several experimental and clinical studies have previously mentioned the association between TNF-α and diabetic...

| Table 4 Comparison between diabetes mellitus cases and controls as regards tumor necrosis factor level |
|-----------------------------------------------|
| N    | Means±SD | P-value | Significance |
| DM cases | 90      | 0.12±0.07 | 0.000 | HS |
| Controls | 48      | 0.03±0.02 |          |     |

DM, diabetes mellitus; HS, highly significant.

| Table 5 Comparison of tumor necrosis factor level between both groups of diabetes mellitus patients |
|-----------------------------------------------|
| N    | Means±SD | P-value | Significance |
| Group I | 60 | 0.14±0.08 | 0.038 | S |
| Group II | 30 | 0.09±0.04 |          |     |

S, significant.

| Table 6 Correlations between personal, biochemical parameters, and clinical scores of peripheral neuropathy and serum tumor necrosis factor level among diabetes mellitus cases with peripheral neuropathy (group I) |
|-----------------------------------------------|
| Personal and biochemical parameters | Correlation coefficient | P-value | Significance |
| Age | 0.533 | 0.016 | S |
| BMI | −0.280 | 0.232 | NS |
| DM duration | 0.234 | 0.320 | NS |
| FBS | 0.232 | 0.324 | NS |
| 2HPP | 0.037 | 0.878 | NS |
| HbA1c (%) | −0.233 | 0.322 | NS |
| Cholesterol | −0.462 | 0.040 | S |
| HDL | −0.190 | 0.423 | NS |
| Triglyceride | −0.266 | 0.257 | NS |
| LDL | −0.341 | 0.142 | NS |
| Score of neuropathy disability symptoms | 0.523 | 0.018 | S |
| Score of clinical PN | 0.464 | 0.039 | S |

DM, diabetes mellitus; FBS, fasting blood sugar; HDL, high density lipoprotein; LDL, low density lipoprotein; PN, peripheral neuropathy; S, significant; 2HPP, 2 hours post prandial.

In the present study, we measured the serum level of TNF-α in type II DM patients with PN and compared such a level with its level in patients with type II DM without neuropathy.

Our study results support the hypothesis that a relationship between serum TNF-α levels and DPN exists. Serum TNF-α was found to be statistically significantly higher in diabetic patients as compared with age-matched and sex-matched controls. Furthermore, serum TNF-α level in DPN patients was found to be much higher than in non-DPN patients (i.e. only DM with no PN).

We found a mixed axonal and demyelinating neuropathy in 65% and a demyelinating neuropathy in 35% of DPN patients. The pattern of neuropathy noted in the present study is consistent with previous neurophysiologic studies undertaken in type 2 diabetic patients [22–25].

In the present study, levels of TNF-α in the DPN patient showed a nonsignificant negative correlation with motor NCV in the median, ulnar, common peroneal, and tibial nerves and sensory NCV in median and sural nerves. Serum TNF-α in DPN patients showed a significant negative correlation with motor amplitudes of both tibial nerves, and no significant correlations were found with motor and sensory amplitudes of other studied nerves.

However, levels of TNF-α in DPN patient showed statistically significant positive correlations with score of neuropathy disability symptoms (NDS) and score of clinical PN (NSS).

Several experimental and clinical studies have previously mentioned the association between TNF-α and diabetic...
neuropathy [26–29]. Matsuda et al. [28] reported a significant negative correlation between the levels of TNF-α and the index of age-corrected sensory NCVs in patients with type 2 DM.

Our results are in accordance with those of Hussain et al. [29], where the mean value of serum TNF-α level was found to be significantly increased in DPN patients of both shorter and longer duration when compared with DM patients without neuropathy. However, a point of contradiction is that Hussain et al. [29] found that TNF-α level in various groups of neuropathy patients showed a statistically significant negative correlation with motor NCV (in the median and ulnar nerves) and sensory NCV (in sural nerve).

This point of contradiction may be attributed to two points of difference between both studies. First, the study by Hussain and colleagues included diabetic patients with clinically detectable PN based on NSS and NDS, whereas the present study included confirmed DPN based on nerve conduction studies. Second, in nerve conduction studies conducted in our patients, we found a mixed axonal and demyelinating neuropathies in 65% and a demyelinating neuropathy in 35% of DPN patients. We found a statistically significant difference in motor amplitudes of median, ulnar common peroneal, and tibial nerves between diabetic patients with PN and those with no PN, whereas motor NCV of median, ulnar common peroneal, and tibial nerves showed a nonsignificant difference between both groups. On the other hand, PN patients in the study of Hussain and colleagues seem to have only demyelinating neuropathies of studied nerves.

However, the study of Duskal et al. [30] was in accordance with our study, in which authors found plasma TNF levels to be significantly higher in type II diabetes patients compared with controls, but no correlations were found between TNF-α levels and conduction velocities in the studied nerves.

High level of TNF-α in serum of type II DPN patients in the present study is supported by the results of Navarro and Mora [31] and Skundrik and Lisak [32] in which the role of neuropoitic cytokines in diabetic PN was analyzed.

Furthermore, previous studies showed that TNF-α contributes to the development of diabetic complications [33,34].

The study of Purwata [1] supports the role of TNF-α in DPN pathogenesis. A positive correlation was found between DPN pain intensity and plasma TNF-α level [1].

In the study of Shi et al. [35], the inhibition of TNF-α in the DPN rats resulted in a significant recovery from DPN signs.

During the pathologic process of DPN, TNF-α may cause nerve dysfunction via multiple pathways. Microvascular damage elicited by TNF-α may cause nerve ischemia and increased vascular permeability, thus permitting the exposure of harmful substances to nerve fibers. On the other hand, local TNF-α exerts demyelination by attacking Schwann cells [36].

Furthermore, the proinflammatory cytokine TNF-α has been implicated in mechanical and thermal hyperalgesia in addition to ectopic firing of sensory neurons [1,37,38], which occurs in a dose-dependent manner [37].

Previous studies have proposed that TNF-α stimulates the expression of specific proteins relevant to cellular damage, such as aldose reductase [39], protein kinase C [40], mitogen-activated protein kinase [41], and inducible nitric oxide synthase [8,42], all of which potentially play a role in the pathogenesis of diabetic polyneuropathy [43]. However, the precise mechanisms of how TNF-α is responsible for the pathogenesis of DPN remain to be elucidated.

As with all studies, there are some limitations. First, the study did not include type I diabetic patients and diabetic patients with good glycemic control, meaning that it would not be possible to directly apply the study results to these groups of diabetic patients. Second, this study could not evaluate the ‘cause and effect’ relationship between elevated serum TNF-α levels and DPN, which is a characteristic of a cross-sectional study. Third, the study population did not include patients with neuropathy due to other etiologies. As such, larger-scale studies that include additional categories of PN patients are warranted in the future.

**Conclusion**

We conclude that serum TNF-α is associated with clinical scores of PN in type II diabetic patients. Significant negative correlations were found with motor amplitudes of both tibial nerves as an index for PN. Thus, we conclude that TNF-α could be used as a biomarker for DPN.

**Financial support and sponsorship**

Nil.
Conflicts of interest
There are no conflicts of interest.

References
1 Purwata TE. High TNF-alpha plasma levels and macrophages iNOS and TNF-alpha expression as risk factors for painful diabetic neuropathy. J Pain Res 2011; 4:169–175.
2 Armati PJ, Pollard JD. Immunology of the Schwann cell. Baillieres Clin Neurol 1996; 5:47–64.
3 Mathei KJ, Funahashi T, Matsuzawa Y, Edelstein S, Bray GA, Kahn SE, Goldberg R. Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes 2003; 52:980–986.
4 Satoh J, Yagashishi S, Toyota T. The possible role of tumor necrosis factor-α in diabetic neuropathy. Exp Diabet Res. 2003; 4:65–71.
5 Schäfers M, Svensson CI, Sommer C, Sorkin LS. Tumor necrosis factor-α induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci 2003; 23:2517–2521.
6 Dinarello CA. Overview of inflammatory cytokines and their role in pain. In: Watkins LR, Maier SF, editors. Cytokines and pain. Basel, Switzerland: Birkhäuser Verlag, 1995. 1–35.
7 Sharma S, Chopra K, Kulkami SK. Effect of insulin and its combination with resveratrol or curcumin in attenuation of diabetic neuropathic pain: participation of nitric oxide and TNF-alpha. Phytother Res 2007; 21:278–283.
8 Ferro TJ, Gertzberg N, Selden L, Neumann P, Johnson A. Endothelial barrier dysfunction and p42 oxidation induced by TNF-alpha are mediated by nitric oxide. Am J Physiol 1997; 272:L979–L988.
9 Samad F, Uysal KT, Wiesbrock SM, Pandey M, Hotamisligil GS, Loskutoff DJ. Tumor necrosis factor α induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci 2003; 23:2517–2521.
10 Martin CL, Albers JW, Pop-Busui R. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes complications study. Endocrinol Metab Clin North Am 1996; 25:303–317.
11 Meijer JW, Boulton AJ, Vendrell J, Amoli MM, Pravica V, Chandrasekar R, Boulton AJ, Larjani B, Hutchinson IV. Vascular risk factors and diabetic neuropathy. N Engl J Med 2003; 352:341–350.
12 Young MJ, Boulton AJ, Maedoe AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36:150–154.
13 Dyck PJ, Albers JW, Andersen H, Arezzo JC, Biessels GJ, Brit V, et al. Diabetic neuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev 2011; 27:620–628.
14 Martin CL, Albers JW, Pop-Busui R. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014; 37:31–38.
15 Kimura J. Electro diagnosis in diseases of nerve and muscle: principles and practice. 198 Madison Avenue, New York: Oxford University Press; 2001.
16 Harati Y. Diabetic neuropathies: unanswered questions. Neurol Clin 2007; 25:303–317.
17 Tesfaye S, Chatuvedi N, Eaton SE, Ward JD, Maires C, Ionescu-Tirgoviste C, Fuller JH. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352:341–350.
18 Takavakko-Bazaz J, Amoli MM, Pravica V, Chandrasekar R, Boulton AJ, Larjani B, Hutchinson IV. VEGF gene polymorphism association with diabetic neuropathy. Mol Biol Rep 2010; 37:3625–3630.
19 Said G, Lacroix C, Lozeron P, Ropert A, Planté V, Adams D. Inflammatory vasculopathy in multifocal diabetic neuropathy. Brain 2003; 126:376–385.
20 Gundogdu BM. Diabetic peripheral neuropathy: an update on pathogenesis and management. Curr Neurol Neurosci Rep 2006; 6:1–4.
21 González-Clemente JM, Mauricio D, Richard C, Brock M, Caixas A, Megia A, Vendrell J. Diabetic neuropathy is associated with activation of the TNF-α system in subjects with type 1 diabetes mellitus. Clin Endocrinol (Oxf) 2005; 63:525–529.
22 Sung JY, Park SB, Liu YT, Kwai N, Arnold R, Krishnan AV, et al. Progressive axonal dysfunction precedes development of neuropathy in type 2 diabetes. Diabetes 2012; 61:1592–1598.
23 Krishnan AV, Lin CS, Kieman MC. Activity-dependent excitability changes suggest Na+/K+ pump dysfunction in diabetic neuropathy. Brain 2008; 131 (Pt 5):1209–1216.
24 Misawa S, Kuwabara S, Ogawara K, Kitano Y, Yagui K, Hattori T. Hyperglycemia alters release of tumor necrosis factor in human diabetic neuropathy. Clin Neurophysiol 2004; 115:2525–2529.
25 Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev 2012; 28(S1):8–14.
26 Zhu T, Meng Q, Ji J, Lou X, Zhang L. Toll-like receptor 4 and tumor necrosis factor-alpha as diagnostic biomarkers for diabetic peripheral neuropathy. Neurosci Lett 2015; 585:28–32.
27 Yamakawa I, Kojima H, Terashima T, Katagi M, Ol J, Urabe H, et al. Inactivation of TNF-alpha ameliorates diabetic neuropathy in mice. Am J Physiol Endocrinol Metab 2011; 301:E844–E852.
28 Matsuda M, Kawasaki F, Inoue H, Kanda Y, Yamada K, Harada Y, et al. Possible contribution of adipokynes on diabetic neuropathy. Diabetes Care Clin Pract 2004; 6(Suppl 1):S121–S123.
29 Hussain G, Rizvi SA, Singhal S, Zubair M, Ahmad J. Serum levels of TNF-α in peripheral neuropathy patients and its correlation with nerve conduction velocity in type 2 diabetes mellitus. Diabetes Metab Syndr 2013; 7:238–242.
30 Dukas T, Tinítkoči Bl, Bilgin S, Kose S, Zorlu Y. Role of inflammation in sensory neuropathy in prediabetes or diabetes. Acta Neurol Scand 2015; 133:384–390.
31 Navarro JP, Mora C. Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy. ScientificWorld Journal 2006; 6:928–937.
32 Skundric DS, Lisak RP. Role of neuropoietic cytokines in development and progression of diabetic polyneuropathy: from glucose metabolism to neurodegeneration. Exp Diabet Res 2003; 4:303–312.
33 Vissarra H. Chronic diabetic complications and tissue glycosylation: relevant concern for diabetes-prone black population. Diabetes Care 1990; 13:1180–1185.
34 King GL, Browtree M. The cellular and molecular mechanisms of diabetic complications. Endocrinol Metab Clin North Am 1996; 25:255–270.
35 Shi X, Chen Y, Nadeem L, Xu G. Beneficial effect of TNF-α inhibition on diabetic peripheral neuropathy. J Neuroinflammation 2013; 10:69.
36 Créange A, Barlovatz-Meimon G, Gherardi RK. Cytokines and peripheral nerve disorders. Eur Cytokine Netw 1997; 8:145–151.
37 Wagner R, Myers RR. Endoneural injection of TNF-α produces neuropathic pain behaviors. Neuroreport 1996; 7:2897–2901.
38 Sorkin LS, Xiao WH, Wagner R, Myers RR. Tumour necrosis factor-alpha induces ectopic activity in nociceptive primary afferent fibres. Neuroscience 1997; 81:255–262.
39 Iwata T, Sato S, Jimenez J, McGowan M, Moroni M, Dey A, Carper D. Osmotic response element is required for the induction of aldose reductase by tumor necrosis factor-α. J Biol Chem 1999; 274:7993–8001.
40 Magnuson DK, Maier RV, Pohrman TH. Protein kinase C: a potential pathway of endothelial cell activation by endotoxin, tumor necrosis factor, and interleukin-1. Surgery 1989; 106:216–222.
41 Igarashi M, Wakasaka H, Takahara N, Ishii H, Jiang ZY, Yamauchi T, King GL. Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways. J Clin Invest 1999; 103:185–195.
42 Muñoz-Fernández MA, Fresno M. The role of tumor necrosis factor, interleukin-6, interferon-γ and inducible nitric oxide synthase in the development and pathology of the nervous system. Prog Neurobiol 1998; 56:307–340.
43 Sima AA, Sugimoto K. Experimental diabetic neuropathy: an update. Diabetologia. 1999; 42:773–788.